अApnaFunda
Menu

VIJAYA DIAGNOSTIC CENTRE LTD (VIJAYA)

Health Services · Medical/Nursing Services · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.67 / 100
Profitability 87Growth 75Balance sheet 39
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.61 / 100
Price 78Earnings 66FII/DII 38

Passes these screensHigh MomentumDebt-light & profitableConsistent compounders

Compare withDR. LAL PATHLABSMETROPOLIS HEALTHCARETHYROCARE TECHNOLOGIES

Share price

Closing priceAdjusted for splits and bonus issues.

₹1,478.3 latest close · +8.3% over the last 90 sessions

₹1,300₹1,400₹1,500Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹1,300₹1,400₹1,500Jul 3Sep 4Nov 9

₹1,478.3 month-end · +48.1% over 12 months

₹800₹1,000₹1,200₹1,400Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹800₹1,000₹1,200₹1,400Nov '25May '26Nov '26

₹1,478.3 month-end · +131.4% over 3 years

₹1,000₹1,500Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹1,000₹1,500Nov '23May '25Nov '26

₹1,478.3 month-end · +159.4% since Sep '21

₹500₹1,000₹1,500Sep '21Sep '22Oct '23Oct '24Nov '25Nov '26 ₹500₹1,000₹1,500Sep '21Apr '24Nov '26

52-week range ₹848.00 to ₹1593.60 · 1-year volatility 32.7%

Was the rally earned?

+48%share price, 1 yearEarnings and multiple

Both mattered.

  • Per-share earnings added 26 points and the multiple added 22 points (P/E 67.9x to 81.1x).
  • The share count barely moved.
Net profit growth: +27 pts. Points of the price return explained by net profit growing (or shrinking).+27 ptsNet profit growthP/E change: +22 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+22 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +48%+48%Share priceNet profit growth: +27 pts. Points of the price return explained by net profit growing (or shrinking).+27ProfitP/E change: +22 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+22P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +48%+48%Share price
Net profit growth+27 ptsNet profit rose about 24%, which lifts the price.
P/E change+22 ptsThe P/E rose from 67.9x to 81.1x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+131%share price, 3 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 123 points to the rise, while the multiple moved less (P/E 77.1x to 81.1x).
  • The share count barely moved.
Net profit growth: +124 pts. Points of the price return explained by net profit growing (or shrinking).+124 ptsNet profit growthP/E change: +8 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+8 ptsP/E changeShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1 ptsShare count changeShare price: +131%+131%Share priceNet profit growth: +124 pts. Points of the price return explained by net profit growing (or shrinking).+124ProfitP/E change: +8 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+8P/EShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1SharesShare price: +131%+131%Share price
Net profit growth+124 ptsNet profit rose about 121%, which lifts the price.
P/E change+8 ptsThe P/E rose from 77.1x to 81.1x, which lifts the price.
Share count change-1 ptsShare count was little changed. More shares would count against the price.
+156%share price, 5 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 131 points to the rise, while the multiple moved less (P/E 69.6x to 81.1x).
  • The share count barely moved.
Net profit growth: +132 pts. Points of the price return explained by net profit growing (or shrinking).+132 ptsNet profit growthP/E change: +25 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+25 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +156%+156%Share priceNet profit growth: +132 pts. Points of the price return explained by net profit growing (or shrinking).+132ProfitP/E change: +25 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+25P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +156%+156%Share price
Net profit growth+132 ptsNet profit rose about 121%, which lifts the price.
P/E change+25 ptsThe P/E rose from 69.6x to 81.1x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with DR. LAL PATHLABS

How rough has the ride been?

Maximum drawdown-53.4%recovered 2023-12
1-year volatility32.7%annualised
Beta vs sector index0.663-year daily, correlation 0.28
Volume spikes1last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%20222023202420252026−51.0% 0%−20%−40%202220242026−51.0%
Largest drawdowns

-53.4% (2021-09 peak to 2022-06 low, recovered 2023-12)

-30.6% (2025-01 peak to 2026-03 low, recovered 2026-05)

-15.8% (2024-10 peak to 2024-10 low, recovered 2024-11)

Most recent volume spikes

2026-08-12: 8x the 50-day median, price +5.8% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

81.1xP/E todayNear its historic high
Against its own history87th percentile
CheapestMedian 69.0xDearest

Usual range 36.8x to 81.5x since 2021-09.

Against Health Services81.1x vs 50.9x
This company
81.1x
Sector median
50.9x

59% above the Health Services median.

29.7x52.5x75.3x98.1xSep '21Oct '22Nov '23Dec '24Jan '26Nov '2629.7x52.5x75.3x98.1xSep '21Jun '23Mar '25Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Services median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Services is valued

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE74th▼ 6 pts vs a year ago
  • Op. margin100th▲ 4 pts vs a year ago
  • Revenue growth58th▼ 17 pts vs a year ago
  • EPS growth72nd▲ 8 pts vs a year ago
  • Debt/equity ↓36thflat vs a year ago
  • Cash cycle ↓93rd▼ 4 pts vs a year ago
  • P/E ↓21st▼ 20 pts vs a year ago
  • 12M momentum89th▲ 65 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What is the price implying?

~37%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 119.8x, a holder earning 12%/yr needs earnings to grow about 37.4%/yr for 10 years, then trade at 15x.

Delivered20.2%/yrEPS, last 9 fiscal years · 3-yr avg to 3-yr avg
Gap+17.2 ptsimplied minus delivered
Rank196thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%19%39% Sep 2021Nov 2026 0%19%39% Sep 2021Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x39.1%40.4%41.6%
15x36.1%37.4%38.6%
20x32.4%33.5%34.7%

Drag a slider to test other assumptions

Implied: 37.4%/yr

Looking back

  • Jan 2022Price implied 29%/yr; EPS has since grown 15%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Services The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹1478.30
P/E
81.1x
ROCE
21.0%
Market Cap
₹15223 cr
Revenue (TTM)
₹857 cr
P/S
17.8x
P/B
15.9x
ROE
19.6%
Operating Margin
43.0%
Debt / Equity
0.4x
Promoter Holding
52.5%
12M Momentum
48.1%

52-week range

₹848.00₹1593.60
85% of the way from its 52-week low to its high

Price risk

1Y volatility
32.7%
Beta vs sector
1-year daily
0.60

Balance sheet & cash

Interest cover
operating profit ÷ interest
7.8x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.55x
Share count, 1Y
unchanged

Are profits backed by cash?

7 of 7checks within rangeAll clear
Other income reliance9%Within range

Other income as a share of pre-tax profit (trailing twelve months): 8.8%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate25%Within range

Median quarterly effective tax rate over about 2.5 years: 25.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.55xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.55x (cash from operations ₹678 cr, net profit ₹437 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+1 daysWithin range

Debtor days are above the median of the previous three fiscal years by 1 days (9 vs 8). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress3% of fixed assetsWithin range

Capital work-in-progress is 3% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-39 days / 2 yrsWithin range

Days payable changed by -39 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, DIIs added 11.8 pts; FIIs trimmed 8.3 pts; promoters trimmed 2.4 pts.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters54.9%52.5%-2.4 pts
FIIs19.9%11.7%-8.3 pts
DIIs19.8%31.6%+11.8 pts
Public and others5.4%4.2%-1.1 pts

Number of shareholders

67,251shareholders+2% since Dec '23
58k61k64k67k Dec '23Jun '24Dec '24Jun '25Dec '25Jun '26
Dec '23: 66,204
Mar '24: 66,724
Jun '24: 62,415
Sep '24: 62,258
Dec '24: 60,952
Mar '25: 66,891
Jun '25: 62,115
Sep '25: 58,994
Dec '25: 57,784
Mar '26: 62,946
Jun '26: 67,251
 58k61k64k67k Dec '23Dec '24Dec '25Jun '26
Dec '23: 66,204
Mar '24: 66,724
Jun '24: 62,415
Sep '24: 62,258
Dec '24: 60,952
Mar '25: 66,891
Jun '25: 62,115
Sep '25: 58,994
Dec '25: 57,784
Mar '26: 62,946
Jun '26: 67,251

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−12.7%typical 12-month return vs the marketBelow the base rate
  • We found 50 past situations where a non-financial company looked like VIJAYA DIAGNOSTIC CENTRE LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −27% to +8% vs the market, against +1% for all non-financial companies in the same months.
  • The analogs' median sat below that base rate (gap −13.5%, 80% range −19.8% to −10.4%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
COHANCE · Jan 2025: −65.9% vs market
ASTEC · Oct 2022: −48.7% vs market
PVRINOX · Feb 2020: −46.5% vs market
EPL · Aug 2020: −46.0% vs market
VENUSPIPES · Apr 2024: −42.5% vs market
UNITDSPR · May 2020: −40.8% vs market
SYMPHONY · Feb 2020: −35.1% vs market
MTARTECH · May 2023: −34.0% vs market
LTTS · Nov 2021: −33.9% vs market
TORNTPHARM · Sep 2020: −32.7% vs market
FLUOROCHEM · Jul 2022: −29.0% vs market
SHREECEM · Jun 2020: −27.0% vs market
SYNGENE · Nov 2020: −26.9% vs market
EMAMILTD · Mar 2021: −25.5% vs market
INDHOTEL · Apr 2025: −24.3% vs market
GODREJCP · Jun 2020: −22.9% vs market
JSWINFRA · Mar 2025: −22.6% vs market
TEGA · Aug 2025: −20.3% vs market
MEDANTA · Apr 2024: −18.5% vs market
ERIS · May 2020: −18.5% vs market
APLLTD · Apr 2020: −17.0% vs market
MAXHEALTH · Jul 2025: −16.3% vs market
KIMS · Aug 2023: −14.0% vs market
HESTERBIO · Oct 2020: −13.8% vs market
JBCHEPHARM · Sep 2023: −12.8% vs market
RAINBOW · Aug 2025: −12.6% vs market
LUXIND · Feb 2020: −9.4% vs market
NH · Jun 2025: −9.3% vs market
ETHOSLTD · Mar 2024: −7.3% vs market
BHARTIHEXA · Oct 2025: −7.1% vs market
SRF · May 2022: −6.3% vs market
CHOICEIN · Sep 2025: −5.9% vs market
AARTIIND · May 2020: −1.3% vs market
LAURUSLABS · May 2021: +0.3% vs market
TASTYBITE · Apr 2020: +0.4% vs market
BERGEPAINT · Jul 2020: +2.3% vs market
JUBLFOOD · Sep 2020: +5.3% vs market
NEOGEN · Jul 2020: +8.4% vs market
METROBRAND · Dec 2022: +13.4% vs market
GARFIBRES · May 2020: +14.8% vs market
PIIND · Jun 2020: +18.4% vs market
KPITTECH · Feb 2023: +26.7% vs market
SOLARINDS · Nov 2021: +28.2% vs market
ASTRAL · Feb 2020: +36.6% vs market
NAVINFLUOR · Jul 2025: +42.3% vs market
ASTRAMICRO · Aug 2025: +51.1% vs market
VBL · Aug 2022: +58.9% vs market
KAYNES · May 2024: +67.9% vs market
ATGL · Jan 2020: +92.3% vs market
POLYMED · Mar 2020: +96.3% vs market
Similar setups −12.7%All companies +0.8%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months

Similar setups' median
−12.7%
All companies' median
+0.8%
Beat the market
34% vs 51%

50 past situations · 50 companies · 34 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
MEDANTA
Health Services		 Apr 2024 119x17% +180%−3% −19%
CHOICEIN
Finance		 Sep 2025 90x20% +64%−7% −6%
RAINBOW
Health Services		 Aug 2025 63x19% +19%−10% −13%
SOLARINDS
Process Industries		 Nov 2021 91x19% +165%−3% +28%
ASTRAL
Producer Manufacturing		 Feb 2020 88x23% +32%−7% +37%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
POLYMED
Health Technology		 Mar 2020 32x22% +6%−29% +96%
SYNGENE
Commercial Services		 Nov 2020 56x17% +82%−2% −27%
METROBRAND
Retail Trade		 Dec 2022 113x20% +93%−8% +13%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and ROCE. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to VIJAYA DIAGNOSTIC CENTRE LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

CHOICE INTERNATIONALCHOICEIN
Finance
81%similar
volatilitymarket cap
NEULAND LABORATORIESNEULANDLAB
Health Technology
60%similar
operating marginrevenue growth
NAVIN FLUORINE INTERNATIONAL LNAVINFLUOR
Process Industries
59%similar
ROCEEPS growth
PRIVI SPECIALITY CHEMICALSPRIVISCL
Process Industries
58%similar
market capvolatility
ANAND RATHI WEALTHANANDRATHI
Finance
57%similar
P/Eoperating margin
RAINBOW CHILDRENS MEDICARERAINBOW
Health Services
62%similar
market capdebt/equity
JUPITER LIFE LINE HOSP.JLHL
Health Services
61%similar
EPS growthdebt/equity
METROPOLIS HEALTHCAREMETROPOLIS
Health Services
60%similar
market capP/E

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Dec '22

  1. AugPeer rankSlipped to the 2nd quartile of Health Services on ROCE (from the top quartile).
  2. AugPriceVolume reached 8.0x its 50-day median on 2026-08-12; price +5.8% that day.
  3. JunPeer rankMoved into the top quartile of Health Services on ROCE (from the 2nd quartile).
  4. MayPriceRegained the 2025-01 peak, 2 months after the low.
  5. MayValuationP/E crossed above the 90th percentile of its own history to date (84.0x).
  6. MayPriceVolume reached 19.9x its 50-day median on 2026-05-11; price +5.0% that day.
  7. MarPriceFell 31% from the Jan 2025 peak to the Mar 2026 low.
  8. JanPeer rankSlipped to the 2nd quartile of Health Services on ROCE (from the top quartile).
Show 22 earlier events
  1. DecPriceVolume reached 76.7x its 50-day median on 2025-12-04; price +7.8% that day.
  2. JulPriceVolume reached 31.2x its 50-day median on 2025-07-24; price +10.2% that day.
  3. JunPeer rankMoved into the top quartile of Health Services on ROCE (from the 2nd quartile).
  4. AprPriceVolume reached 24.3x its 50-day median on 2025-04-08; price +13.9% that day.
  5. MarPriceVolume reached 40.4x its 50-day median on 2025-03-04; price +6.8% that day.
  6. NovPriceVolume reached 15.5x its 50-day median on 2024-11-08; price +9.2% that day.
  7. SepValuationP/E crossed above the 90th percentile of its own history to date (79.2x).
  8. AugPriceVolume reached 21.4x its 50-day median on 2024-08-20; price +7.1% that day.
  9. JunResultsYear-on-year EPS growth turned positive.
  10. JunPeer rankMoved into the top quartile of Health Services on EPS growth (from the 3rd quartile).
  11. MayPriceVolume reached 89.3x its 50-day median on 2024-05-10; price +9.9% that day.
  12. AprValuationP/E crossed above the 90th percentile of its own history to date (84.4x).
  13. FebPriceVolume reached 22.6x its 50-day median on 2024-02-07; price +6.2% that day.
  14. DecPriceRegained the 2021-09 peak, 18 months after the low.
  15. NovPriceVolume reached 19.3x its 50-day median on 2023-11-10; price +6.6% that day.
  16. OctValuationP/E crossed above the 90th percentile of its own history to date (70.8x).
  17. SepPriceVolume reached 6.2x its 50-day median on 2023-09-18; price -1.8% that day.
  18. JunResultsYear-on-year EPS growth turned negative.
  19. JunPeer rankSlipped to the 2nd quartile of Health Services on ROCE (from the top quartile).
  20. AprPriceVolume reached 80.3x its 50-day median on 2023-04-27; price +9.8% that day.
  21. MarPriceVolume reached 81.0x its 50-day median on 2023-03-27; price +16.5% that day.
  22. DecPriceVolume reached 42.3x its 50-day median on 2022-12-22; price -6.2% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history63 months · 2021-09 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1181.1x₹857 cr19.6%21.0%0.4x
2026-1079.3x₹857 cr19.5%21.0%0.4x
2026-0978.9x₹857 cr19.5%21.0%0.4x
2026-0890.2x₹814 cr18.1%21.0%0.4x
2026-0779.9x₹814 cr18.1%21.0%0.4x
2026-0680.4x₹814 cr18.1%21.0%0.4x
2026-0584.0x₹768 cr20.0%21.0%0.4x
2026-0472.5x₹768 cr20.0%21.0%0.4x
2026-0355.3x₹768 cr20.0%21.0%0.4x
2026-0267.9x₹732 cr19.0%21.0%0.4x
2026-0164.8x₹732 cr19.0%21.0%0.4x
2025-1271.7x₹732 cr19.0%21.0%0.4x
2025-1167.9x₹713 cr18.9%21.0%0.4x
2025-1067.3x₹713 cr18.9%21.0%0.4x
2025-0968.1x₹713 cr18.9%21.0%0.4x
2025-0872.0x₹681 cr18.0%21.0%0.4x
2025-0776.8x₹681 cr18.0%21.0%0.4x
2025-0670.4x₹681 cr18.0%21.0%0.4x
2025-0569.0x₹663 cr21.8%20.0%0.4x
2025-0472.2x₹663 cr21.8%20.0%0.4x
2025-0372.7x₹663 cr21.8%20.0%0.4x
2025-0270.7x₹627 cr20.4%20.0%0.4x
2025-0179.8x₹627 cr20.4%20.0%0.4x
2024-1281.5x₹627 cr20.4%20.0%0.4x
2024-1196.3x₹583 cr19.2%20.0%0.4x
2024-1082.4x₹583 cr19.2%20.0%0.4x
2024-0979.2x₹583 cr19.2%20.0%0.4x
2024-0878.5x₹548 cr18.3%20.0%0.4x
2024-0768.0x₹548 cr18.3%20.0%0.4x
2024-0664.4x₹548 cr18.3%20.0%0.4x
2024-0598.1x₹459 cr15.6%18.0%0.5x
2024-0484.4x₹459 cr15.6%18.0%0.5x
2024-0376.8x₹459 cr15.6%18.0%0.5x
2024-0277.7x₹459 cr15.6%18.0%0.5x
2024-0179.7x₹459 cr15.6%18.0%0.5x
2023-1281.5x₹459 cr15.6%18.0%0.5x
2023-1177.1x₹459 cr15.6%18.0%0.5x
2023-1070.8x₹459 cr15.6%18.0%0.5x
2023-0960.2x₹459 cr15.6%18.0%0.5x
2023-0862.8x₹459 cr15.6%18.0%0.5x
2023-0754.2x₹459 cr15.6%18.0%0.5x
2023-0657.0x₹459 cr15.6%18.0%0.5x
2023-0535.7x₹462 cr23.7%28.0%0.4x
2023-0435.1x₹462 cr23.7%28.0%0.4x
2023-0336.4x₹462 cr23.7%28.0%0.4x
2023-0235.1x₹462 cr23.7%28.0%0.4x
2023-0138.3x₹462 cr23.7%28.0%0.4x
2022-1240.6x₹462 cr23.7%28.0%0.4x
2022-1145.5x₹462 cr23.7%28.0%0.4x
2022-1040.6x₹462 cr23.7%28.0%0.4x
2022-0942.8x₹462 cr23.7%28.0%0.4x
2022-0833.0x₹462 cr23.7%28.0%0.4x
2022-0731.7x₹462 cr23.7%28.0%0.4x
2022-0631.0x₹462 cr23.7%28.0%0.4x
2022-0543.9x₹377 cr23.7%27.0%0.4x
2022-0455.3x₹377 cr23.7%27.0%0.4x
2022-0352.9x₹377 cr23.7%27.0%0.4x
2022-0250.9x₹377 cr23.7%27.0%0.4x
2022-0162.4x₹377 cr23.7%27.0%0.4x
2021-1270.4x₹377 cr23.7%27.0%0.4x
2021-1169.6x₹377 cr23.7%27.0%0.4x
2021-1068.2x₹377 cr23.7%27.0%0.4x
2021-0968.8x₹377 cr23.7%27.0%0.4x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback